See more : GEOTECH SEISMIC SE (GTSS.ME) Income Statement Analysis – Financial Results
Complete financial analysis of Invivyd, Inc. (IVVD) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Invivyd, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Suzuki Motor Corporation (SZKMY) Income Statement Analysis – Financial Results
- ATA Creativity Global (AACG) Income Statement Analysis – Financial Results
- Matthews International Corporation (MATW) Income Statement Analysis – Financial Results
- BioAtla, Inc. (BCAB) Income Statement Analysis – Financial Results
- LFG Investment Holdings Limited (3938.HK) Income Statement Analysis – Financial Results
Invivyd, Inc. (IVVD)
About Invivyd, Inc.
Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease. Adagio Therapeutics, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was incorporated in 2020 and is based in Waltham, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 2.03M | 462.00K | 1.00K | 0.00 |
| Gross Profit | -2.03M | -462.00K | -1.00K | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 158.66M | 179.21M | 182.89M | 62.12M |
| General & Administrative | 0.00 | 47.04M | 36.52M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 47.10M | 47.04M | 36.52M | 3.21M |
| Other Expenses | 0.00 | 6.71M | 118.00K | 0.00 |
| Operating Expenses | 205.76M | 226.26M | 219.41M | 65.33M |
| Cost & Expenses | 207.78M | 226.26M | 219.41M | 65.33M |
| Interest Income | 0.00 | 6.71M | 118.00K | 8.00K |
| Interest Expense | 0.00 | 43.08M | 0.00 | 0.00 |
| Depreciation & Amortization | 2.03M | 462.00K | 1.00K | 43.20M |
| EBITDA | -196.62M | -248.03M | -226.79M | -65.33M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -207.78M | -248.03M | -226.91M | -65.33M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 9.14M | 6.71M | -7.38M | 8.00K |
| Income Before Tax | -198.64M | -241.32M | -226.79M | -65.32M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -6.71M | 7.50M | -43.20K |
| Net Income | -198.64M | -234.60M | -234.29M | -65.32M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.81 | -2.17 | -2.11 | -0.59 |
| EPS Diluted | -1.81 | -2.17 | -2.11 | -0.59 |
| Weighted Avg Shares Out | 109.53M | 108.27M | 110.78M | 111.25M |
| Weighted Avg Shares Out (Dil) | 109.53M | 108.27M | 110.78M | 111.25M |
Invivyd, Inc (IVVD) Q4 2022 Earnings Call Transcript
Invivyd, Inc (NASDAQ:IVVD ) Q4 2022 Earnings Conference Call March 23, 2023 4:30 PM ET Company Participants Kyra Faircloth - Investor Relations Dave Hering - Chief Executive Officer Pete Schmidt - Chief Medical Officer Lukas Dillinger - Interim Head, Discovery...
Invivyd to Host Conference Call Discussing Full Year 2022 Financial Results and Business Highlights
WALTHAM, Mass., March 16, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced that it will host a conference call on Thursday, March...
FILING DEADLINE–Kuznicki Law PLLC Announces Class Action on Behalf of Shareholders of Invivyd, Inc. – IVVD, ADGI
CEDARHURST, N.Y., March 8, 2023 /PRNewswire/ — The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of Invivyd, Inc. (the “Company”) (NasdaqGM: IVVD) f/k/a Adagio Therapeutics, Inc. (“Adagio”) (NasdaqGM: ADGI), if they purchased the Company’s...
INVIVYD SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Invivyd To Contact Him Directly To Discuss Their Options
NEW YORK, March 4, 2023 /PRNewswire/ — Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. (“Invivyd” or the “Company”) (NASDAQ: IVVD) and reminds investors of the April...
INVIVYD SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Invivyd, Inc. – IVVD, ADGI
NEW ORLEANS, Feb. 10, 2023 /PRNewswire/ — ClaimsFiler, a FREE shareholder information service, reminds investors that they have until April 3, 2023 to file lead plaintiff applications in a securities class action lawsuit against Invivyd, Inc. (the “Company”) (NasdaqGM: IVVD)...
IVVD Stock: 7.89% Decrease Explained
The stock price of Invivyd Inc (NASDAQ: IVVD) fell by 7.89% in the most recent trading session. This is why.
Why Shares of Invivyd Jumped This Week
The company's shares have climbed along since an FDA announcement earlier this week.
Invivyd, Inc. (IVVD) Upgraded to Buy: Here's Why
Invivyd, Inc. (IVVD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Invivyd, Inc. (IVVD) CEO David Hering on Q3 2022 Results - Earnings Call Transcript
Invivyd, Inc. (NASDAQ:IVVD ) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Kyra Faircloth - VP, Government Affairs, Advocacy and Corporate Communication David Hering - CEO Laura Walker - Chief Scientific Officer Fred Driscoll -...
Invivyd to Present Multiple Posters Highlighting Clinical Data from Adintrevimab During ID Week 2022
WALTHAM, Mass., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Invivyd, (Nasdaq: IVVD), formerly Adagio Therapeutics (Nasdaq: ADGI), a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases announced today that it will have four poster presentations...
Source: https://incomestatements.info
Category: Stock Reports